On this episode we're joined by Andrea DiMella - VP & Head of Talent at Atlas Venture - to get her insight into the evolving talent landscape in biotechnology.
We talk through Andrea's transition from a laboratory scientist into a transformative TA leader through roles with Genentech, Biogen, Third Rock, and now Atlas Venture. Her learnings throughout this journey are shaping the TA strategy of some of the most exciting biotechs in the Atlas portfolio.
Tune in to hear more about Andrea's perspective on building influential teams & company creation, when to provide hands-on support & when to let C-teams 'fly solo', and of course, Andrea's take on AI in talent acquisition.
Rita is the CEO of Muna Therapeutics, a biotech company focused on discovering and developing therapies that restore the function of diseased neurons and slow or stop neurodegeneration.
In this conversation, we explore Rita’s career journey and what inspired their move into biotech leadership, as well as what first drew them to Muna Therapeutics. We talk about Muna’s scientific focus, how their approach to neurodegenerative diseases stands apart, and what it takes to lead a globally distributed team.
We also dive into the culture they’re building at Muna — one that encourages innovation and resilience — and look ahead at what’s next for the company over the coming year.
Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn.
Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies.
Now at CytoDyn, Robert is helping steer the company as itadvances its lead monoclonal antibody program.
This conversation is about leadership, staying motivated inbiotech’s toughest cycles, and the big vision for CytoDyn’s future.
Today, we’re joined by an extraordinary leader who has spent her career at the intersection of science, innovation, and human potential — Dr. Sheila Gujrathi.
Sheila is a physician, scientist, engineer, and biotech entrepreneur whose journey embodies both precision and purpose. She earned her Bachelor’s degree in Biomedical Engineering and her M.D. from Northwestern University, before completing her residency at Brigham and Women’s Hospital / Harvard Medical School and fellowships in Allergy and Immunology at UCSF and Stanford.
Her career has been defined by bold leadership and groundbreaking innovation — from leading global immunology programs at Bristol-Myers Squibb, to serving as Chief Medical Officer at Receptos, where she helped advance the drug Zeposia® to approval for multiple sclerosis and ulcerative colitis. She went on to co-found and serve as CEO of Gossamer Bio, and today she chairs the boards of Ventyx Biosciences and Lila Biologics, while serving as a director at Janux Therapeutics.
But beyond her professional success, Sheila is known for her authenticity, her advocacy for diversity and inclusion in biotech, and her belief in leading with empathy, curiosity, and courage. Through her writing and mentorship, she challenges us to bring our whole selves to our work — reminding us that science and leadership are at their best when they’re deeply human.
On this episode we're joined by the Co-Founder & CEO of Tr1X, David de Vries.
David and the team are building on the Nobel Prize winning research into T-reg cells of Fred Ramsdell, Shimon Sakaguchi, and Mary Brunkow, pushing that science forward by translating a Type-1 regulatory T cell program into the clinic with one goal - lasting immune balance for patients.
Their lead program TRX103 is in ph1/2 trials for GvHD and Refractory Crohn's, whilst they just received another IND clearance for TRX319, an allogeneic CD19 CAR-Tr1 therapy, to tackle Progressive MS. Tr1X pick hard problems on purpose & these indications demonstrate that.
David is an impressive leader, having co-founded Arine, and was nominated recently in BioSpace's 40 under 40 list. Tr1X are one to watch, we hope you'll enjoy the episode!
We were honoured to welcome Neha Krishnamohan, onto The BioHub.
Neha began her professional journey at Goldman Sachs in theHealthcare Investment Banking Group, focusing on mergers & acquisitions and strategic financings for biotech and med-tech companies. During her time there, she helped execute more than $100 billion in transactions across biopharma, diagnostics and tools.
Building on that foundation, Neha then moved into anoperational leadership role in biotech: she served as CFO and Executive Vice President of Corporate Development at Kinnate Biopharma, a precision-oncology company, where she led financial operations, business development and investor relations — working through strategic alternatives that culminated in asset transactions and acquisition.
Most recently, she joined Artiva Biotherapeutics, aclinical-stage company focused on off-the-shelf natural-killer (“NK”) cell therapies for autoimmune diseases and cancer, as CFO & EVP Corporate Development (April 2024). Her role is helping drive the company’s growthstrategy, financing, M&A and operational execution as Artiva scales its pipeline.
On this episode of the BioHub Podcast we’re joined by the CEO of Alzinova, Tord Labuda. Alzinova are a Gothenburg-based biotech developing an Alzheimer’s vaccine that's just received FDA IND approval and will soon step into ph2 trials.
Alzinova’s products have been developed using their proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) peptide so that it only forms the soluble (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process.
Alzinova's mission is to bring true disease-modifying therapy to Alzheimer’s patients. By using the proprietary AβCC technology, Alzinova can develop therapies that are unique in that they target Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.
Welcome to The Biohub
Joy Clark, Chief People Officer at Worldwide Clinical Trials, joins The BioHub Podcast to talk about building belonging, leading with purpose, and driving health equity in clinical research. Joy shares her journey from high-growth tech to the CRO world, how Worldwide has cultivated a culture that’s 73% women, and why human-centered leadership matters more than ever.
We were thrilled to welcome, Heather Turner, CEO of LB Pharmaceuticals, onto The BioHub. Heather is a seasoned biotechnology executive with over 25 years of experience driving legal, operational, and strategic excellence across the biopharmaceutical industry. She currently serves as CEO of LB Pharmaceuticals, a clinical-stage company focused on innovative treatments for schizophrenia. Under her leadership, LB recently went public in a landmark IPO, marking a major milestone in the company’s growth journey.
Prior to LB, Heather led Carmot Therapeutics through a $3.1 billion acquisition by Roche, expanded teams, and executed transformative financing and strategic initiatives. With deep expertise in navigating complex biotech landscapes, Heather’s insights span corporate strategy, IPOs, and driving innovation in clinical-stage development. We’re excited to hear her perspective on leadership, biotech growth, and the future of medicine
Today, we’re joined by Clarke Atwell, CEO of Claris Biotherapeutics — a company pioneering regenerative biologic therapies with a focus on transforming the field of ophthalmology.Under Clarke’s leadership, Claris has achieved a major milestone with its Series A financing, fueling the company’s mission to advance novel therapies designed to repair and restore vision at the cellular level, and are now in the process of going through there series B round. By combining cutting-edge biology with a deep understanding of ocular disease, Claris is working to address some of the most challenging conditions in eye health.Clarke’s career spans scientific innovation and executive leadership across the biopharma industry, and he now leads Claris through an exciting new chapter of growth and clinical translation.
Today I’m joined by Dr. Maurits Geerlings, President and CEOof NanoCell Therapeutics.
Maurits is a true biotech entrepreneur — he’s co-founded and built multiple companies including Actinium Pharmaceuticals, Formula Pharmaceuticals, and Mirata Pharma — and now he’s on a mission to revolutionize in-vivo cell engineering.
In this conversation, we dive into Maurits’ journey, the unique structure of NanoCell, the challenges and opportunities in cell therapy right now, and his bold vision for the future of this field.
Enjoy and stay tuned.
Amir Inamdar is the Chief Medical Officer at Cybin Inc., bringing more than 20 years of clinical medicine and drug-development experience. Prior to joining Cybin, Amir held senior roles in industry including Senior Medical Director for R&D Neurosciences at AstraZeneca, Medical Director at Takeda Development Centre Europe Ltd., and Director of Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline. He's led global teams in advancing novel therapies across indications such as treatment-resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance-use disorders — and steered compounds from preclinical development through first-in-human and proof-of-concept studies
Today I’m joined by Dena House - Chief People Officer atAdverum Biotechnologies.
Dena’s career has spanned some of the world’s leading life sciences companies, from Nikon Precision to Myriad Genetics, but what stands out is her passion for building strong, intentional culture in complex organizations.
At Adverum, she was brought in with a clear mission: buildthe kind of people-first culture that can power innovation, resilience, and long-term growth, even in one of biotech’s toughest markets.
We talk about how she tackled that challenge, what greatculture actually looks like in biotech, and why this work matters more now than ever.
Let’s get into it.
We were delighted to welcome Baruch Harris, Chief Operating Officer at Pretzel Therapeutics, a company dedicated to translating mitochondrial biology into transformative therapies. Dr. Harris’s journey spans from rigorous scientific roots to strategic leadership — he holds a Ph.D. in Biochemistry and Molecular Biology from UCSF and a degree in Biophysics from Brown University. Before joining Pretzel, he led business development, operations, and fundraising efforts at companies including ROME Therapeutics, Yumanity Therapeutics, Metera Pharmaceuticals, and Enlight Biosciences. In our conversation today, we’ll explore how Pretzel is tackling mitochondrial dysfunction as a therapeutic target, the unique operational challenges of scaling a biotech platform grounded in mitochondrial biology.
Welcome back to another episode of The BioHub, we were delighted to welcome on Abid Ansari, Chief Financial Officer at General Oncology, a clinical-stage biopharma company focused on first-in-class therapies for metastatic cancer. With more than two decades of experience in the biotechnology and life sciences sectors, Abid has built his reputation as a strategic finance executive who bridges capital, innovation, and growth. Over his career, he’s led major capital raises — including a $153 million Series C at Artios and a $146 million IPO at Precision BioSciences — and driven business development deals, licensing agreements, and M&A transactions. Earlier in his journey, Abid held roles at GSK in deal finance and portfolio management, contributing to high-stakes transactions such as the acquisition of Bristol Myers Squibb’s HIV portfolio and licensing agreements with Adaptimmune
I’m joined by Dr. Paul Song, Chairman & CEO of NKGen Biotech.
Paul has led across biotech, from CMO at NKGEN to co-founding Fuse Biotherapeutics and since 2022 he’s been driving NKGen’s mission to harness natural killer cells through their proprietary SNK platform for neurodegenerative diseases and cancer.
In this episode, we dive into his decision to return and lead NKGen, the science behind the SNK platform, the company’s recent SPAC merger and NASDAQ listing, and his perspective on building resilient biotech companies in today’s market.Enjoy and stay tuned.
On this episode we had the pleasure of featuring Roy Maute of Pheast Therapeutics.
Pheast are unleashing the power of macrophages in oncology, starting in advanced solid tumours & Ovarian Cancer. Their pipeline consists of novel innate immune checkpoint inhibitors (incl. Anti-CD24), based on research out of Irv Weissman's lab at Stanford.
In this episode we cover the inspiration behind Roy's career in oncology R&D & the origins of Pheast's name & platform, before moving onto Pheast's recent (FTD, ph1 entry) and upcoming milestones. We also cover their big ambitions for the future & how their huge focus on culture as a business has & continues to shape their journey.
Today, we're joined by Dr. Tatiana Novobrantseva, the Chief Scientific Officer at NextPoint Therapeutics, a clinical-stage biotech company pioneering precision immuno-oncology therapies targeting the novel HHLA2 (B7-H7) pathway.Tatiana brings over two decades of expertise in immunology, cancer, immuno-oncology, autoimmunity, and fibrosis. She co-founded Verseau Therapeutics in 2017, serving as CSO and advancing novel immunotherapies that stimulate macrophage repolarization to initiate anti-cancer immune responses. Prior to that, she led oncology discovery and development projects at Moderna as Chief Scientific Officer, Immuno-Oncology Research.At NextPoint, Tatiana is leading the development of therapies targeting the B7-H7 immune checkpoint pathway, aiming to reactivate exhausted T and NK cells in solid tumors. This approach offers a promising alternative for patients who have not responded to traditional PD-1/CTLA-4 therapies.Dr. Novobrantseva earned her Ph.D. in immunology from the University of Cologne in Germany and completed postdoctoral research at Harvard Medical School in the laboratory of Dr. Klaus Rajewsky, focusing on B cell immunology and autoimmunity
Welcome back to another episode of The BioHub, we weredelighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups like Iota Biosciences and Opsis Therapeutics. Under his guidance, Kenai Therapeutics has secured groundbreaking funding and is advancing life-changing therapies for patientswith Parkinson’s disease. He holds an MBA from Northwestern University’s
Kellogg School of Management and a BBA from the University of Wisconsin, bringing a rare combination of business acumen and scientific vision to the table. Nick joins us today to share his insights on pioneering stem celltherapies, building biotech startups from the ground up, and what it takes to turn cutting-edge science into real-world solutions.
Today’s guest is someone who’s seen biotech from both sidesof the table—first as an investor, and now as a builder.
I’m joined by Punit Dhillon, CEO of Skye Bioscience, wherehe’s leading one of the most exciting stories in metabolic health.
Punit started Skye as employee number one and has sincebuilt it into a clinical-stage company with one first-in-class programs and backing from major life science investors like 5AM and Versant. With a background in finance and business development—and a career that includes partnerships with Merck, Genentech, BMS and Pfizer—he brings a unique anddeeply strategic lens to biotech leadership.
In this episode, we dig into the mindset it takes to buildfrom the ground up, the wave of innovation in obesity, and how Skye is carving out its own lane in one of the most competitive markets in biotech.